Australian Patient's 100 Days on Titanium Heart Sets Medical Milestone

2025-03-14 transformation

Australia, Friday, 14 March 2025.
An Australian man became the first to be discharged with the BiVACOR titanium heart, surviving over 100 days before a transplant. This development marks a new era in artificial heart technology.

Groundbreaking Surgery and Recovery

The revolutionary procedure took place at St Vincent’s Hospital Sydney in November 2024, with the six-hour operation marking a significant milestone in cardiac medicine [1][3]. The patient, a man in his forties who was critically ill with heart failure, became not only the sixth person globally to receive the BiVACOR device but notably the first to survive beyond a month with it [2]. The success culminated in his discharge in early February 2025, followed by a successful donor heart transplant on March 3, 2025 [3].

Innovative Technology Behind BiVACOR

The BiVACOR Total Artificial Heart represents a significant advancement in artificial heart technology, utilizing magnetic levitation technology with just one moving part - a suspended rotor that propels blood throughout the body [1][2]. This innovative design, developed by biomedical engineer Daniel Timms, significantly reduces mechanical wear compared to traditional devices that typically rely on multiple moving parts [4]. The device connects to an external controller through a cord tunneled under the skin, powered by batteries during daytime use and mains power at night [2].

Global Impact and Future Prospects

The implications of this success are profound, particularly considering that heart failure affects over 23 million people worldwide, with only approximately 6,000 donor hearts available annually [5]. In the United States alone, nearly 7 million adults live with heart failure, while only 4,500 heart transplants were performed in 2023 [1]. Looking ahead, the Victor Chang Cardiac Research Institute anticipates that artificial hearts could become a viable alternative for patients unable to wait for donor hearts within the next decade [5]. The technology’s future development includes plans to integrate electronics within the body and implement charging through the skin using electromagnetic induction within five to six years [5].

Expanding Clinical Applications

The success has prompted further clinical trials, with the U.S. Food and Drug Administration approving 15 additional human trials [6]. In Australia, the Artificial Heart Frontiers Program at Monash University has scheduled four more BiVACOR device implantations for 2025 [3]. The Alfred Hospital in Melbourne is preparing for its first BiVACOR implantation, scheduled for mid-2025 [3]. This expansion of the program represents a crucial step toward addressing the significant gap between heart failure patients and available donor organs [1][5].

Bronnen

Titanium heart BiVACOR